<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02919995</url>
  </required_header>
  <id_info>
    <org_study_id>RPL554-010-2015</org_study_id>
    <secondary_id>2015-004263-36</secondary_id>
    <nct_id>NCT02919995</nct_id>
  </id_info>
  <brief_title>A Study of RPL554 in Patients With Cystic Fibrosis</brief_title>
  <official_title>A Phase IIa, Randomised, Double Blind, Placebo Controlled, Three Way Crossover Study to Assess the Pharmacokinetics of RPL554 Administered to Adult Patients With Cystic Fibrosis.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Verona Pharma plc</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Cystic Fibrosis Trust</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Verona Pharma plc</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study evaluates two doses of RPL554 and placebo in adult patients with cystic fibrosis.
      All patients receive all three treatments in a randomised sequence.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">February 8, 2017</start_date>
  <completion_date type="Actual">November 3, 2017</completion_date>
  <primary_completion_date type="Actual">November 3, 2017</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>AUC by Dose</measure>
    <time_frame>Pre dose, 15 and 30 minutes and 1, 2, 4, 6, 8 and 24 hours post dose after each treatment</time_frame>
    <description>Area under the curve (AUC)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Maximum Plasma Concentration After Each Dose</measure>
    <time_frame>Pre dose, 15 and 30 minutes and 1, 2, 4, 6, 8 and 24 hours post dose</time_frame>
    <description>Maximum plasma concentration (Cmax) after a single dose of RPL554</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Time to Maximum Plasma Concentration After Each Dose</measure>
    <time_frame>Pre dose, 15 and 30 minutes and 1, 2, 4, 6, 8 and 24 hours post dose</time_frame>
    <description>Time to maximum concentration (Tmax) after a single dose of RPL554</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Half Life for Each Dose</measure>
    <time_frame>Pre dose, 15 and 30 minutes and 1, 2, 4, 6, 8 and 24 hours post dose</time_frame>
    <description>Half life (t1/2) of RPL554</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Peak FEV1 for Each Treatment</measure>
    <time_frame>Pre dose and 15 and 30 minutes and 1, 2 and 4 hours post dose after treatment</time_frame>
    <description>Maximum Forced expired volume in one second (FEV1) measured using spirometry</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>AUC FEV1(0-4h)</measure>
    <time_frame>Pre dose and 15 and 30 minutes and 1, 2 and 4 hours post dose</time_frame>
    <description>Area under the curve for FEV1 over 4 hours measured using spirometry</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>AUC FEV1(0-6h)</measure>
    <time_frame>Pre dose and 15 and 30 minutes and 1, 2, 4 and 6 hours post dose</time_frame>
    <description>Area under the curve FEV1 over 6 hours measured using spirometry</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>AUC FEV1(0-8h)</measure>
    <time_frame>pre dose and 15 and 30 minutes and 1, 2, 4, 6 and 8 hours post dose</time_frame>
    <description>Area under the curve for FEV1 over 8 hours measured using spirometry</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>FVC</measure>
    <time_frame>Over 24 hours after treatment</time_frame>
    <description>Forced vital capacity (FVC) measured using spirometry</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Breath Samples</measure>
    <time_frame>8 and 24 hours after treatment</time_frame>
    <description>Exhaled breath pH</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Laboratory Safety Tests 1</measure>
    <time_frame>Screening and end of study</time_frame>
    <description>Biochemistry panel parameters</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Laboratory Safety Tests 2</measure>
    <time_frame>Screening and end of study</time_frame>
    <description>Haematology panel parameters</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Laboratory Safety Tests 3</measure>
    <time_frame>Screening and end of study</time_frame>
    <description>Urinalysis measured by urine dipstick</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Vital Signs 1</measure>
    <time_frame>Over 8 hours after treatment</time_frame>
    <description>Pulse rate after 5 minutes supine</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Vital Signs 2</measure>
    <time_frame>Over 8 hours after treatment</time_frame>
    <description>Blood pressure after 5 minutes supine</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>ECG 1</measure>
    <time_frame>Over 8 hours after treatment</time_frame>
    <description>Heart rate</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>ECG 2</measure>
    <time_frame>Over 8 hours after treatment</time_frame>
    <description>QT interval</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Sputum Rheology</measure>
    <time_frame>8 and 12 hours after treatment</time_frame>
    <description>Rheological analysis for interleukin 8, tumour necrosis factor alpha and myeloperoxidase</description>
  </other_outcome>
  <other_outcome>
    <measure>Sputum Measurements</measure>
    <time_frame>8 and 12 hours after treatment</time_frame>
    <description>Levels of inflammatory mediators</description>
  </other_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">10</enrollment>
  <condition>Cystic Fibrosis</condition>
  <arm_group>
    <arm_group_label>Higher Dose RPL554</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Single dose of inhaled 6 mg RPL554</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Lower dose RPL554</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Single dose of inhaled 1.5 mg RPL554</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Inhaled placebo dose</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>RPL554</intervention_name>
    <description>RPL554 suspension administered using a nebuliser</description>
    <arm_group_label>Higher Dose RPL554</arm_group_label>
    <arm_group_label>Lower dose RPL554</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo solution administered using a nebuliser</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  1. Sign an informed consent document indicating they understand the purpose of and
             procedures required for the study and are willing to participate in the study.

             2. Male or female aged ≥18 years at the time of informed consent. Females of
             childbearing potential must have been using a consistent and reliable form of
             contraception (see Appendix 1) from the last menses before the first study treatment
             administration, and must commit to continue to do so during the study and for 3 months
             after the last dose of study treatment.

             3. Have a 12-lead ECG recording at screening (Visit 1) and Visit 2 pre-dose showing
             the following:

               -  Heart rate between 45 and 90 beats per minute

               -  QT interval corrected for heart rate using Fridericia's formula (QTcF) interval
                  ≤450 msec

               -  QRS interval ≤120 msec

               -  PR interval ≤220 msec

               -  No clinically significant abnormality including morphology (e.g. left bundle
                  branch block, atrioventricular nodal dysfunction, ST segment abnormalities) 4.
                  Capable of complying with all study restrictions and procedures including ability
                  to use the study nebuliser correctly.

                  5. Body mass index (BMI) between 18 and 30 kg/m2 (inclusive) with a minimum
                  weight of 40 kg.

                  6. Patients with a genetic diagnosis of CF. 7. Spirometry at screening
                  demonstrating an FEV1 ≥40% and ≤80% of predicted normal.

                  8. Capable of withdrawing from long acting bronchodilators1 until the end of the
                  treatment period, and short acting bronchodilators for 8 hours prior to
                  administration of study treatment.

                  9. Clinically stable CF in the 2 weeks prior to randomisation (Visit 2).

        Exclusion Criteria:

          1. History of cirrhotic liver disease or portal hypertension.

          2. CF exacerbation requiring hospitalisation in the month prior to screening (Visit 1) or
             prior to randomisation (Visit 2).

          3. Use of oral or intravenous antibiotics (in additional to usual maintenance therapy) in
             the 2 weeks prior to screening (Visit 1) or randomisation (Visit 2).

          4. Other non-CF related respiratory disorders: Patients with a current diagnosis of
             active tuberculosis, lung cancer, sarcoidosis, sleep apnoea, known alpha-1 antitrypsin
             deficiency or other active pulmonary diseases.

          5. Previous lung resection or lung transplant.

          6. History of, or reason to believe a patient has, drug or alcohol abuse within the past
             3 years.

          7. Received an experimental drug within 3 months or five half-lives, whichever is longer.

          8. Patients with a history of chronic uncontrolled disease including, but not limited to,
             cardiovascular (including arrhythmias), endocrine, active hyperthyroidism,
             neurological, hepatic, gastrointestinal, renal, haematological, urological,
             immunological or ophthalmic diseases that the Investigator believes are clinically
             significant.

          9. Documented cardiovascular disease: angina, recent or suspected myocardial infarction,
             congestive heart failure, a history of unstable, or uncontrolled hypertension, or has
             been diagnosed with hypertension in last 3 months.

         10. Has had major surgery, (requiring general anaesthesia) in the 6 weeks prior to
             screening (Visit 1) or will not have fully recovered from surgery, or planned surgery
             through the end of the study.

         11. Infection with nontuberculous mycobacteria, methicillin-resistant Staphylococcus
             aureus (MRSA), or Burkholderia species.

         12. Use of immune-suppression; long term use of prednisolone ≥10 mg/day.

         13. History of malignancy of any organ system within 5 years with the exception of
             localised skin cancers (basal or squamous cell).

         14. Clinically significant abnormal values for safety laboratory tests (haematology,
             biochemistry or urinalysis) at screening (Visit 1), as determined by the Investigator.

         15. A disclosed history or one known to the Investigator, of significant non-compliance in
             previous investigational studies or with prescribed medications.

         16. Requires oxygen therapy, even on an occasional basis.

         17. Pregnancy or lactation (female subjects only).

         18. Any other reason that the Investigator considers makes the patient unsuitable to
             participate. -
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Andres Floto</last_name>
    <role>Principal Investigator</role>
    <affiliation>Cambridge Centre for Medical Research, Papworth Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Papworth Hospital</name>
      <address>
        <city>Cambridge</city>
        <zip>CB23 3RE</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United Kingdom</country>
  </location_countries>
  <verification_date>May 2019</verification_date>
  <study_first_submitted>September 21, 2016</study_first_submitted>
  <study_first_submitted_qc>September 27, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 30, 2016</study_first_posted>
  <results_first_submitted>December 7, 2018</results_first_submitted>
  <results_first_submitted_qc>December 7, 2018</results_first_submitted_qc>
  <results_first_posted type="Actual">March 20, 2019</results_first_posted>
  <last_update_submitted>May 6, 2019</last_update_submitted>
  <last_update_submitted_qc>May 6, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">May 14, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cystic Fibrosis</mesh_term>
    <mesh_term>Fibrosis</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Statistical Analysis Plan</document_type>
      <document_has_protocol>No</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>January 3, 2018</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/95/NCT02919995/SAP_000.pdf</document_url>
    </provided_document>
    <provided_document>
      <document_type>Study Protocol</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>No</document_has_sap>
      <document_date>August 23, 2017</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/95/NCT02919995/Prot_001.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <pre_assignment_details>16 patients were screened; six patients failed screening. Patients had to discontinue long acting bronchodilators on the day prior to screening and short acting bronchodilators for 8 hours before all spirometry assessments</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Higher Dose RPL554/Lower Dose RPL554/Placebo</title>
          <description>Single dose of inhaled 6 mg RPL554 in Period 1, Single inhaled dose of 1.5 mg RPL554 in Period 2, placebo in Period 3
RPL554: RPL554 suspension administered using a nebuliser Placebo: Placebo solution administered using a nebuliser</description>
        </group>
        <group group_id="P2">
          <title>Lower Dose RPL554/Placebo/Higher Dose RPL554</title>
          <description>Single dose of inhaled 1.5 mg RPL554 in Period 1, single inhaled dose of placebo in Period 2, single inhaled dose of 6 mg RPL554 in Period 3
RPL554: RPL554 suspension administered using a nebuliser Placebo: Placebo solution administered using a nebuliser</description>
        </group>
        <group group_id="P3">
          <title>Higher Dose RPL554/Plaebo/Lower Dose RPL554</title>
          <description>Single inhaled dose of 6 mg RPL554 in Period 1, single inhaled dose of placebo in Period 2, single inhaled dose of 1.5 mg RPL554 in Period 3
RPL554: RPL554 suspension administered using a nebuliser Placebo: Placebo solution administered using a nebuliser</description>
        </group>
        <group group_id="P4">
          <title>Lower Dose RPL554/Higher Dose RPL554/Placebo</title>
          <description>Single inhaled dose of 1.5 mg RPL554 in Period 1, single inhaled dose of 6 mg RPL554 in Period 2, single inhaled dose of placebo in Period 3
RPL554: RPL554 suspension administered using a nebuliser Placebo: Placebo solution administered using a nebuliser</description>
        </group>
        <group group_id="P5">
          <title>Placebo/Higher Dose RPL554/Lower Dose RPL554</title>
          <description>Single inhaled dose of placebo in Period 1, single inhaled dose of 6 mg RPL554 in Period 2, single inhaled dose of 1.5 mg RPL554 in Period 3
RPL554: RPL554 suspension administered using a nebuliser Placebo: Placebo solution administered using a nebuliser</description>
        </group>
        <group group_id="P6">
          <title>Placebo/Lower Dose RPL554/Higher Dose RPL554</title>
          <description>Single inhaled dose of placebo in Period 1, single inhaled dose of 1.5 mg RPL554 in Period 2, single inhaled dose of 6 mg RPL554 in Period 3
RPL554: RPL554 suspension administered using a nebuliser Placebo: Placebo solution administered using a nebuliser</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="2"/>
                <participants group_id="P3" count="2"/>
                <participants group_id="P4" count="2"/>
                <participants group_id="P5" count="1"/>
                <participants group_id="P6" count="2"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="2"/>
                <participants group_id="P3" count="2"/>
                <participants group_id="P4" count="2"/>
                <participants group_id="P5" count="1"/>
                <participants group_id="P6" count="1"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="1"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Higher Dose RPL554/Lower Dose RPL554/Placebo</title>
          <description>Single dose of inhaled 6 mg RPL554 in Period 1, single dose of inhaled 1.5 mg RPL554 in Period 2, single inhaled dose of placebo in Period 3
RPL554: RPL554 suspension administered using a nebuliser Placebo: Placebo solution administered using a nebuliser</description>
        </group>
        <group group_id="B2">
          <title>Lower Dose RPL554/Placebo/Higher Dose RPL554</title>
          <description>Single dose of inhaled 1.5 mg RPL554 in Period 1, single dose of inhaled placebo RPL554 in Period 2, single dose of 6 mg RPL554 in Period 3
RPL554: RPL554 suspension administered using a nebuliser Placebo: Placebo solution administered using a nebuliser</description>
        </group>
        <group group_id="B3">
          <title>Higher Dose RPL554/Placebo/Lower Dose RPL554</title>
          <description>Single dose of inhaled 6 mg RPL554 in Period 1, single dose of inhaled placebo in Period 2, single dose of inhaled 1.5 mg RPL554 in Period 3
RPL554: RPL554 suspension administered using a nebuliser Placebo: Placebo solution administered using a nebuliser</description>
        </group>
        <group group_id="B4">
          <title>Lower Dose RPL554/Higher Dose RPL554/Placebo</title>
          <description>Single dose of inhaled 1.5 mg RPL554 in Period 1, single dose of inhaled 6 mg RPL554 in Period 2, single inhaled dose of placebo in Period 3
RPL554: RPL554 suspension administered using a nebuliser Placebo: Placebo solution administered using a nebuliser</description>
        </group>
        <group group_id="B5">
          <title>Placebo/Higher Dose RPL554/Lower Dose RPL554</title>
          <description>Single dose of inhaled placebo in Period 1, single dose of inhaled 6 mg RPL554 in Period 2, single dose of inhaled 1.5 mg RPL554 in Period 3
RPL554: RPL554 suspension administered using a nebuliser Placebo: Placebo solution administered using a nebuliser</description>
        </group>
        <group group_id="B6">
          <title>Placebo/Lower Dose RPL554/Higher Dose RPL554</title>
          <description>Single dose of inhaled placebo in Period 1, single dose of inhaled 1.5 mg RPL554 in Period 2, single dose of inhaled 6 mg RPL554 in Period 3
RPL554: RPL554 suspension administered using a nebuliser Placebo: Placebo solution administered using a nebuliser</description>
        </group>
        <group group_id="B7">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="1"/>
            <count group_id="B2" value="2"/>
            <count group_id="B3" value="2"/>
            <count group_id="B4" value="2"/>
            <count group_id="B5" value="1"/>
            <count group_id="B6" value="2"/>
            <count group_id="B7" value="10"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="0"/>
                    <measurement group_id="B7" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="2"/>
                    <measurement group_id="B4" value="2"/>
                    <measurement group_id="B5" value="1"/>
                    <measurement group_id="B6" value="2"/>
                    <measurement group_id="B7" value="10"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="0"/>
                    <measurement group_id="B7" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="2"/>
                    <measurement group_id="B4" value="1"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="1"/>
                    <measurement group_id="B7" value="4"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="1"/>
                    <measurement group_id="B5" value="1"/>
                    <measurement group_id="B6" value="1"/>
                    <measurement group_id="B7" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="0"/>
                    <measurement group_id="B7" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="0"/>
                    <measurement group_id="B7" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="0"/>
                    <measurement group_id="B7" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="0"/>
                    <measurement group_id="B7" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="2"/>
                    <measurement group_id="B4" value="2"/>
                    <measurement group_id="B5" value="1"/>
                    <measurement group_id="B6" value="2"/>
                    <measurement group_id="B7" value="10"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="0"/>
                    <measurement group_id="B7" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="0"/>
                    <measurement group_id="B7" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>AUC by Dose</title>
        <description>Area under the curve (AUC)</description>
        <time_frame>Pre dose, 15 and 30 minutes and 1, 2, 4, 6, 8 and 24 hours post dose after each treatment</time_frame>
        <population>All randomised patients with blood sampling performed after at least one dose of RPL554 and with data sufficient to calculate pharmacokinetic parameters.</population>
        <group_list>
          <group group_id="O1">
            <title>Higher Dose RPL554</title>
            <description>Single dose of inhaled 6 mg RPL554
RPL554: RPL554 suspension administered using a nebuliser</description>
          </group>
          <group group_id="O2">
            <title>Lower Dose RPL554</title>
            <description>Single dose of inhaled 1.5 mg RPL554
RPL554: RPL554 suspension administered using a nebuliser</description>
          </group>
        </group_list>
        <measure>
          <title>AUC by Dose</title>
          <description>Area under the curve (AUC)</description>
          <population>All randomised patients with blood sampling performed after at least one dose of RPL554 and with data sufficient to calculate pharmacokinetic parameters.</population>
          <units>pg*h/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="9"/>
                <count group_id="O2" value="9"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7699" spread="2965.7"/>
                    <measurement group_id="O2" value="2342" spread="1029.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Maximum Plasma Concentration After Each Dose</title>
        <description>Maximum plasma concentration (Cmax) after a single dose of RPL554</description>
        <time_frame>Pre dose, 15 and 30 minutes and 1, 2, 4, 6, 8 and 24 hours post dose</time_frame>
        <population>All randomised patients with blood sampling performed after at least one dose of RPL554 and with data sufficient to calculate pharmacokinetic parameters.</population>
        <group_list>
          <group group_id="O1">
            <title>Higher Dose RPL554</title>
            <description>Single dose of inhaled 6 mg RPL554
RPL554: RPL554 suspension administered using a nebuliser</description>
          </group>
          <group group_id="O2">
            <title>Lower Dose RPL554</title>
            <description>Single dose of inhaled 1.5 mg RPL554
RPL554: RPL554 suspension administered using a nebuliser</description>
          </group>
        </group_list>
        <measure>
          <title>Maximum Plasma Concentration After Each Dose</title>
          <description>Maximum plasma concentration (Cmax) after a single dose of RPL554</description>
          <population>All randomised patients with blood sampling performed after at least one dose of RPL554 and with data sufficient to calculate pharmacokinetic parameters.</population>
          <units>pg/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="9"/>
                <count group_id="O2" value="9"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="828.3" spread="256.1"/>
                    <measurement group_id="O2" value="270.1" spread="91.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Time to Maximum Plasma Concentration After Each Dose</title>
        <description>Time to maximum concentration (Tmax) after a single dose of RPL554</description>
        <time_frame>Pre dose, 15 and 30 minutes and 1, 2, 4, 6, 8 and 24 hours post dose</time_frame>
        <population>All randomised patients with blood sampling performed after at least one dose of RPL554 and with data sufficient to calculate pharmacokinetic parameters.</population>
        <group_list>
          <group group_id="O1">
            <title>Higher Dose RPL554</title>
            <description>Single dose of inhaled 6 mg RPL554
RPL554: RPL554 suspension administered using a nebuliser</description>
          </group>
          <group group_id="O2">
            <title>Lower Dose RPL554</title>
            <description>Single dose of inhaled 1.5 mg RPL554
RPL554: RPL554 suspension administered using a nebuliser</description>
          </group>
        </group_list>
        <measure>
          <title>Time to Maximum Plasma Concentration After Each Dose</title>
          <description>Time to maximum concentration (Tmax) after a single dose of RPL554</description>
          <population>All randomised patients with blood sampling performed after at least one dose of RPL554 and with data sufficient to calculate pharmacokinetic parameters.</population>
          <units>hours</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="9"/>
                <count group_id="O2" value="9"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.53" spread="0.66"/>
                    <measurement group_id="O2" value="1.33" spread="0.62"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Half Life for Each Dose</title>
        <description>Half life (t1/2) of RPL554</description>
        <time_frame>Pre dose, 15 and 30 minutes and 1, 2, 4, 6, 8 and 24 hours post dose</time_frame>
        <population>All randomised patients with blood sampling performed after at least one dose of RPL554 and with data sufficient to calculate pharmacokinetic parameters.</population>
        <group_list>
          <group group_id="O1">
            <title>Higher Dose RPL554</title>
            <description>Single dose of inhaled 6 mg RPL554
RPL554: RPL554 suspension administered using a nebuliser</description>
          </group>
          <group group_id="O2">
            <title>Lower Dose RPL554</title>
            <description>Single dose of inhaled 1.5 mg RPL554
RPL554: RPL554 suspension administered using a nebuliser</description>
          </group>
        </group_list>
        <measure>
          <title>Half Life for Each Dose</title>
          <description>Half life (t1/2) of RPL554</description>
          <population>All randomised patients with blood sampling performed after at least one dose of RPL554 and with data sufficient to calculate pharmacokinetic parameters.</population>
          <units>Hours</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="9"/>
                <count group_id="O2" value="9"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10.14" spread="3.1"/>
                    <measurement group_id="O2" value="7.52" spread="3.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Peak FEV1 for Each Treatment</title>
        <description>Maximum Forced expired volume in one second (FEV1) measured using spirometry</description>
        <time_frame>Pre dose and 15 and 30 minutes and 1, 2 and 4 hours post dose after treatment</time_frame>
        <population>All randomized patients with sufficient data collected after intake of study treatment to compute the pharmacodynamic parameters on at least two study visits.</population>
        <group_list>
          <group group_id="O1">
            <title>Higher Dose RPL554</title>
            <description>Single dose of inhaled 6 mg RPL554
RPL554: RPL554 suspension administered using a nebuliser</description>
          </group>
          <group group_id="O2">
            <title>Lower Dose RPL554</title>
            <description>Single dose of inhaled 1.5 mg RPL554
RPL554: RPL554 suspension administered using a nebuliser</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Inhaled placebo dose
Placebo: Placebo solution administered using a nebuliser</description>
          </group>
        </group_list>
        <measure>
          <title>Peak FEV1 for Each Treatment</title>
          <description>Maximum Forced expired volume in one second (FEV1) measured using spirometry</description>
          <population>All randomized patients with sufficient data collected after intake of study treatment to compute the pharmacodynamic parameters on at least two study visits.</population>
          <units>Liters</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="9"/>
                <count group_id="O2" value="10"/>
                <count group_id="O3" value="10"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.384" spread="0.73"/>
                    <measurement group_id="O2" value="2.247" spread="0.72"/>
                    <measurement group_id="O3" value="2.256" spread="0.71"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>0.0196</p_value>
            <method>ANCOVA</method>
            <param_type>Contrast ratio</param_type>
            <param_value>1.038</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>1.007</ci_lower_limit>
            <ci_upper_limit>1.07</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>0.0802</p_value>
            <method>ANCOVA</method>
            <param_type>Contrast ratio</param_type>
            <param_value>1.024</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.997</ci_lower_limit>
            <ci_upper_limit>1.052</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>0.3487</p_value>
            <method>ANCOVA</method>
            <param_type>Contrast ratio</param_type>
            <param_value>0.986</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.957</ci_lower_limit>
            <ci_upper_limit>1.017</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>AUC FEV1(0-4h)</title>
        <description>Area under the curve for FEV1 over 4 hours measured using spirometry</description>
        <time_frame>Pre dose and 15 and 30 minutes and 1, 2 and 4 hours post dose</time_frame>
        <population>All randomized patients with sufficient data collected after intake of study treatment to compute the pharmacodynamic parameters on at least two study visits.</population>
        <group_list>
          <group group_id="O1">
            <title>Higher Dose RPL554</title>
            <description>Single dose of inhaled 6 mg RPL554
RPL554: RPL554 suspension administered using a nebuliser</description>
          </group>
          <group group_id="O2">
            <title>Lower Dose RPL554</title>
            <description>Single dose of inhaled 1.5 mg RPL554
RPL554: RPL554 suspension administered using a nebuliser</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Inhaled placebo dose
Placebo: Placebo solution administered using a nebuliser</description>
          </group>
        </group_list>
        <measure>
          <title>AUC FEV1(0-4h)</title>
          <description>Area under the curve for FEV1 over 4 hours measured using spirometry</description>
          <population>All randomized patients with sufficient data collected after intake of study treatment to compute the pharmacodynamic parameters on at least two study visits.</population>
          <units>Liters</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="9"/>
                <count group_id="O2" value="10"/>
                <count group_id="O3" value="10"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.313" spread="0.73"/>
                    <measurement group_id="O2" value="2.194" spread="0.72"/>
                    <measurement group_id="O3" value="2.133" spread="0.73"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>0.0043</p_value>
            <method>ANCOVA</method>
            <param_type>Contrast ratio</param_type>
            <param_value>1.072</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>1.026</ci_lower_limit>
            <ci_upper_limit>1.12</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>0.0109</p_value>
            <method>ANCOVA</method>
            <param_type>Contrast ratio</param_type>
            <param_value>1.055</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>1.014</ci_lower_limit>
            <ci_upper_limit>1.096</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>0.4306</p_value>
            <method>ANCOVA</method>
            <param_type>Contrast ratio</param_type>
            <param_value>0.984</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.942</ci_lower_limit>
            <ci_upper_limit>1.027</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>AUC FEV1(0-6h)</title>
        <description>Area under the curve FEV1 over 6 hours measured using spirometry</description>
        <time_frame>Pre dose and 15 and 30 minutes and 1, 2, 4 and 6 hours post dose</time_frame>
        <population>all randomized patients with sufficient data collected after intake of study treatment to compute the pharmacodynamic parameters on at least two study visits.</population>
        <group_list>
          <group group_id="O1">
            <title>Higher Dose RPL554</title>
            <description>Single dose of inhaled 6 mg RPL554
RPL554: RPL554 suspension administered using a nebuliser</description>
          </group>
          <group group_id="O2">
            <title>Lower Dose RPL554</title>
            <description>Single dose of inhaled 1.5 mg RPL554
RPL554: RPL554 suspension administered using a nebuliser</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Inhaled placebo dose
Placebo: Placebo solution administered using a nebuliser</description>
          </group>
        </group_list>
        <measure>
          <title>AUC FEV1(0-6h)</title>
          <description>Area under the curve FEV1 over 6 hours measured using spirometry</description>
          <population>all randomized patients with sufficient data collected after intake of study treatment to compute the pharmacodynamic parameters on at least two study visits.</population>
          <units>Liters</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="9"/>
                <count group_id="O2" value="10"/>
                <count group_id="O3" value="10"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.304" spread="0.74"/>
                    <measurement group_id="O2" value="2.188" spread="0.73"/>
                    <measurement group_id="O3" value="2.133" spread="0.73"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>0.0064</p_value>
            <method>ANCOVA</method>
            <param_type>Contrast ratio</param_type>
            <param_value>1.065</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>1.021</ci_lower_limit>
            <ci_upper_limit>1.11</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>0.0149</p_value>
            <method>ANCOVA</method>
            <param_type>Contrast ratio</param_type>
            <param_value>1.049</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>1.011</ci_lower_limit>
            <ci_upper_limit>1.089</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>0.466</p_value>
            <method>ANCOVA</method>
            <param_type>Contrast ratio</param_type>
            <param_value>0.945</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.945</ci_lower_limit>
            <ci_upper_limit>1.027</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>AUC FEV1(0-8h)</title>
        <description>Area under the curve for FEV1 over 8 hours measured using spirometry</description>
        <time_frame>pre dose and 15 and 30 minutes and 1, 2, 4, 6 and 8 hours post dose</time_frame>
        <population>All randomised patients with sufficient data collected after intake of study treatment to compute the pharmacodynamic parameters on at least two study visits.</population>
        <group_list>
          <group group_id="O1">
            <title>Higher Dose RPL554</title>
            <description>Single dose of inhaled 6 mg RPL554
RPL554: RPL554 suspension administered using a nebuliser</description>
          </group>
          <group group_id="O2">
            <title>Lower Dose RPL554</title>
            <description>Single dose of inhaled 1.5 mg RPL554
RPL554: RPL554 suspension administered using a nebuliser</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Inhaled placebo dose
Placebo: Placebo solution administered using a nebuliser</description>
          </group>
        </group_list>
        <measure>
          <title>AUC FEV1(0-8h)</title>
          <description>Area under the curve for FEV1 over 8 hours measured using spirometry</description>
          <population>All randomised patients with sufficient data collected after intake of study treatment to compute the pharmacodynamic parameters on at least two study visits.</population>
          <units>Liters</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="9"/>
                <count group_id="O2" value="10"/>
                <count group_id="O3" value="10"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.287" spread="0.75"/>
                    <measurement group_id="O2" value="2.185" spread="0.74"/>
                    <measurement group_id="O3" value="2.130" spread="0.74"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>0.0093</p_value>
            <method>ANCOVA</method>
            <param_type>Contrast ratio</param_type>
            <param_value>1.061</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>1.017</ci_lower_limit>
            <ci_upper_limit>1.107</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>0.0333</p_value>
            <method>ANCOVA</method>
            <param_type>Contrast ratio</param_type>
            <param_value>1.042</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>1.004</ci_lower_limit>
            <ci_upper_limit>1.082</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>0.3693</p_value>
            <method>ANCOVA</method>
            <param_type>Contrast ratio</param_type>
            <param_value>0.982</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.941</ci_lower_limit>
            <ci_upper_limit>1.024</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>FVC</title>
        <description>Forced vital capacity (FVC) measured using spirometry</description>
        <time_frame>Over 24 hours after treatment</time_frame>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Breath Samples</title>
        <description>Exhaled breath pH</description>
        <time_frame>8 and 24 hours after treatment</time_frame>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Laboratory Safety Tests 1</title>
        <description>Biochemistry panel parameters</description>
        <time_frame>Screening and end of study</time_frame>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Laboratory Safety Tests 2</title>
        <description>Haematology panel parameters</description>
        <time_frame>Screening and end of study</time_frame>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Laboratory Safety Tests 3</title>
        <description>Urinalysis measured by urine dipstick</description>
        <time_frame>Screening and end of study</time_frame>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Vital Signs 1</title>
        <description>Pulse rate after 5 minutes supine</description>
        <time_frame>Over 8 hours after treatment</time_frame>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Vital Signs 2</title>
        <description>Blood pressure after 5 minutes supine</description>
        <time_frame>Over 8 hours after treatment</time_frame>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>ECG 1</title>
        <description>Heart rate</description>
        <time_frame>Over 8 hours after treatment</time_frame>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>ECG 2</title>
        <description>QT interval</description>
        <time_frame>Over 8 hours after treatment</time_frame>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Sputum Rheology</title>
        <description>Rheological analysis for interleukin 8, tumour necrosis factor alpha and myeloperoxidase</description>
        <time_frame>8 and 12 hours after treatment</time_frame>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Sputum Measurements</title>
        <description>Levels of inflammatory mediators</description>
        <time_frame>8 and 12 hours after treatment</time_frame>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>From informed consent through study completion, up to 52 days</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Higher Dose RPL554</title>
          <description>Single dose of inhaled 6 mg RPL554
RPL554: RPL554 suspension administered using a nebuliser</description>
        </group>
        <group group_id="E2">
          <title>Lower Dose RPL554</title>
          <description>Single dose of inhaled 1.5 mg RPL554
RPL554: RPL554 suspension administered using a nebuliser</description>
        </group>
        <group group_id="E3">
          <title>Placebo</title>
          <description>Inhaled placebo dose
Placebo: Placebo solution administered using a nebuliser</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA 19.1</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="10"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>exacerbation of cystic fibrosis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="10"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_vocab>MedDRA 19.1</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="9"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="10"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="10"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Tachycardia</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="9"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="10"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="10"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal pain lower</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Dry mouth</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="9"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="10"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Chest discomfort</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="9"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="10"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Immune system disorders</title>
            <event_list>
              <event>
                <sub_title>Drug hypersensitivity</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="10"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Infective exacerbation of cystic fibrosis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Oral candidiasis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="9"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="10"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Forced expiratory volume decreased</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="9"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Pulmonary function test decreased</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="10"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Back pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="10"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Syncope</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="10"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Cough</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="9"/>
                <counts group_id="E2" events="2" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Nasal congestion</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Rhinorrhoea</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="9"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="10"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>The Investigator shall not be permitted to present at symposia, national or regional professional meetings, nor publish in journals, theses or dissertations, or otherwise of their own choosing, methods and results of the Clinical Trial without the prior written approval of the Sponsor. Any such approved presentation or publication shall acknowledge the Sponsor as the sponsor of the Clinical Trial and owner of the results of the Clinical Trial.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Brian Maurer</name_or_title>
      <organization>Verona Pharma plc</organization>
      <phone>+19147675037</phone>
      <email>brian.maurer@veronapharma.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

